Recent advances in the biomarkers for epithelial ovarian cancer.
作者信息
Kim Yun Hwan, Kim Seung Cheol
机构信息
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Woman's University Mokdong Hospital, Ewha Woman's University School of Medicine, Seoul, Korea.
出版信息
J Gynecol Oncol. 2011 Dec;22(4):219-21. doi: 10.3802/jgo.2011.22.4.219. Epub 2011 Dec 5.
Abstract
摘要
相似文献
1
Recent advances in the biomarkers for epithelial ovarian cancer.上皮性卵巢癌生物标志物的最新进展
J Gynecol Oncol. 2011 Dec;22(4):219-21. doi: 10.3802/jgo.2011.22.4.219. Epub 2011 Dec 5.
2
The role of biomarkers in the management of epithelial ovarian cancer.生物标志物在上皮性卵巢癌管理中的作用。
Expert Rev Mol Diagn. 2017 Jun;17(6):577-591. doi: 10.1080/14737159.2017.1326820. Epub 2017 May 15.
3
Current clinical use of biomarkers for epithelial ovarian cancer.当前上皮性卵巢癌生物标志物的临床应用。
Curr Opin Oncol. 2010 Sep;22(5):492-7. doi: 10.1097/CCO.0b013e32833c3351.
4
[Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].[多种生物标志物悬浮阵列技术用于卵巢癌的临床验证]
Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):11-19. doi: 10.3760/cma.j.issn.0529-567X.2017.01.005.
5
MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer.微小RNA：一种用于卵巢癌诊断和预后的新型且有前景的潜在生物标志物。
Cancer Biol Med. 2015 Dec;12(4):328-41. doi: 10.7497/j.issn.2095-3941.2015.0024.
6
Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer.术前血清中五种生物标志物的水平与上皮性卵巢癌中这些标志物与癌症分期的相关性。
J Gynecol Oncol. 2009 Sep;20(3):169-75. doi: 10.3802/jgo.2009.20.3.169. Epub 2009 Sep 30.
7
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.上皮性卵巢癌生物标志物检测的建议：西班牙病理学会和西班牙肿瘤内科学会的国家共识声明。
Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16.
8
The emerging role of CXC chemokines in epithelial ovarian cancer.CXCL 趋化因子在卵巢上皮性癌中的新作用。
Reproduction. 2012 Sep;144(3):303-17. doi: 10.1530/REP-12-0153. Epub 2012 Jul 6.
9
[The molecular biology of epithelial ovarian cancer].[上皮性卵巢癌的分子生物学]
Bull Cancer. 2012 Dec;99(12):1161-73. doi: 10.1684/bdc.2012.1667.
10
Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.高度侵袭性和中度侵袭性的小鼠卵巢癌细胞系表现出不同的基因表达。
Tumour Biol. 2016 Aug;37(8):11147-11162. doi: 10.1007/s13277-015-4518-4. Epub 2016 Mar 2.
引用本文的文献
1
Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.利用 MALDI-TOF 和三重四极杆飞行时间质谱联用技术进行血清代谢物分析，以开发卵巢癌筛查方法。
Cancer Res Treat. 2018 Jul;50(3):883-893. doi: 10.4143/crt.2017.275. Epub 2017 Sep 18.
2
Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer.应激诱导磷蛋白1（STIP1）的表达与上皮性卵巢癌的肿瘤进展及不良预后相关。
Genes Chromosomes Cancer. 2014 Apr;53(4):277-88. doi: 10.1002/gcc.22136. Epub 2014 Feb 1.
3
Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer.奥沙利铂、亚叶酸钙和 5-氟尿嘧啶（FOLFOX-4）化疗在复发性上皮性卵巢癌重度预处理患者中的可行性。
Cancer Res Treat. 2013 Mar;45(1):40-7. doi: 10.4143/crt.2013.45.1.40. Epub 2013 Mar 31.
本文引用的文献
1
Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer.基于晚期上皮性卵巢癌患者术后最低 CA-125 水平预测高危人群。
J Gynecol Oncol. 2011 Dec;22(4):269-74. doi: 10.3802/jgo.2011.22.4.269. Epub 2011 Dec 5.
2
Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.评估疑似卵巢囊性肿块患者的卵巢癌标志物 HE4 和 CA-125。
J Gynecol Oncol. 2011 Dec;22(4):244-52. doi: 10.3802/jgo.2011.22.4.244. Epub 2011 Dec 5.
3
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.筛查对卵巢癌死亡率的影响：前列腺癌、肺癌、结直肠癌和卵巢癌（PLCO）癌症筛查随机对照试验。
JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.
4
The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.国家癌症数据库报告：晚期上皮性卵巢癌：医院手术病例量对总生存和手术治疗模式的影响。
Gynecol Oncol. 2010 Sep;118(3):262-7. doi: 10.1016/j.ygyno.2010.05.025. Epub 2010 Jun 22.
5
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.新型多指标联合检测与风险恶性指数在盆腔包块患者上皮性卵巢癌预测中的比较。
Am J Obstet Gynecol. 2010 Sep;203(3):228.e1-6. doi: 10.1016/j.ajog.2010.03.043. Epub 2010 May 14.
6
Development of a multimarker assay for early detection of ovarian cancer.开发一种用于早期检测卵巢癌的多标志物检测方法。
J Clin Oncol. 2010 May 1;28(13):2159-66. doi: 10.1200/JCO.2008.19.2484. Epub 2010 Apr 5.
7
Quality of care in advanced ovarian cancer: the importance of provider specialty.晚期卵巢癌的护理质量：提供者专业的重要性。
Gynecol Oncol. 2010 Apr;117(1):18-22. doi: 10.1016/j.ygyno.2009.12.033. Epub 2010 Jan 27.
8
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.血清人附睾蛋白4（HE4）浓度可区分恶性卵巢肿瘤与卵巢子宫内膜异位囊肿。
Br J Cancer. 2009 Apr 21;100(8):1315-9. doi: 10.1038/sj.bjc.6605011. Epub 2009 Mar 31.
9
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).多模式及超声筛查卵巢癌的敏感性和特异性，以及所检测癌症的分期分布：英国卵巢癌筛查协作试验（UKCTOCS）患病率筛查结果
Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.
10
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.一种利用人附睾蛋白4（HE4）和癌抗原125（CA125）预测盆腔肿块患者卵巢癌的新型多标志物生物测定法。
Gynecol Oncol. 2009 Jan;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12.
Zotero 插件